Cannabis Law Report

JUNE 15, 2021

. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.

Decriminalization 78

Decriminalization Policy Research and Development Data 78

Cannabis Law Report

FEBRUARY 28, 2022

Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Controlled Substance Schedules , DRUG ENF’T ADMIN., [link] [ [link] ] (defining DEA criteria for categorization in Schedule I and listing psychedelic examples such as lysergic acid diethylamide (LSD), peyote, and MDMA).

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

MAY 1, 2019

8 In January of this year, Attorney General Jeff Sessions rescinded an Obama-era policy which had de-prioritized federal prosecution of those involved in the cannabis industry in states which had legalized medical or recreational cannabis. any other Federal criminal statute.” 31 See Lisa N. 32 See , e.g., Retail Marijuana Rules, 1 Colo.

Legalization 45

Legalization Business Law Cannabis 45

Cannabis Law Report

JULY 1, 2021

The Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. POPLAR will publish original law and policy research. CR: Can you describe the existing landscape of psychedelics research?

Law 105

Law Research and Development Therapy DEA 105

MJ Business Attorneys

MARCH 1, 2018

CannaTech showcases the biggest industry thought leaders, known for their significant and groundbreaking contributions to the global cannabis market in fields such as science, finance, government policy and tech. ” and he will be discussing the following: A brief history of the U.S. policy towards marijuana.

DEA 100

DEA Policy History Compliance 100

Cannabis Law Report

SEPTEMBER 23, 2019

During the 20 th century, law enforcement and public policy activities have undermined opportunities for scientific exploration. Relevant AAFP Policy. Family physicians have a vested interest in policies that advance and protect the health of their patients and the public. Marijuana Possession for Personal Use. Call to Action.

Cannabinoids 40

Cannabinoids Marijuana Research and Development Access 40

Cannabis Law Report

APRIL 8, 2022

To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52